A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents

Neurogastroenterology and Motility

Volumn 23, Issue 9, 2011, Pages

  Lin, X H ^a   Yuece, B ^b   Li, Young Yu ^a   Feng, Y J ^a   Feng, J Y ^a   Yu, L Y ^a   Li, K ^a   Li, Y N ^a   Storr, Martin ^b,c  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cannabidiol; G protein coupled receptor 55; Intestinal movement; Lipopolysaccharide; O 1602

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABIDIOL; CANNABINOID RECEPTOR AGONIST; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; LIPOPOLYSACCHARIDE; O 1602; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL MOTILITY; HISTOPATHOLOGY; ILEUS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTESTINE CONTRACTION; JEJUNUM; MEMBRANE POTENTIAL; MOUSE; MUSCLE CELL; MYOELECTRICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY;

ANIMALS; CANNABIDIOL; ELECTROMYOGRAPHY; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; INDOLES; INFLAMMATION; INTERLEUKIN-6; INTESTINES; LIGANDS; LIPOPOLYSACCHARIDES; MEMBRANE POTENTIALS; MICE; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; PIPERIDINES; PYRAZOLES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051683607     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01742.x     Document Type: Article

References (42)

1. Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 2007; 7: 575-82.
2. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100.
3. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009; 60: 77-84.
4. Aviello G, Romano B, Izzo AA. Cannabinoids and gastrointestinal motility: animal and human studies. Eur Rev Med Pharmacol Sci 2008; 12(Suppl 1): 81-93.
5. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008; 7: 438-55.
6. Wise A, Brown AJ. Glaxosmithkline. Identification of modulators of GPR55 activity. 2001; WO/2001/086305.
7. Drmota T, Greasley P, Groblewski T. Astrazeneca. Screening assays for cannabinoid-ligand type modulators of GPR55. 2004; WO/2004/074844.
8. Brown AJ, Ueno S, Suen K, Dowell SJ, Wise A. Molecular identification of GPR55 as a third G protein-coupled receptor responsive to cannabinoid ligands. In: Brian Thomas, ed 2005 Symposium on the Cannabinoids. Burlington, VT: International Cannabinoid Research Society, Abstr, 2005: 16.
9. Sjögren S, Ryberg E, Lindblom A et al. A new receptor for cannabinoid ligands. In: Brian Thomas, ed. 2005 Symposium on the Cannabinoids. Burlington, VT, International Cannabinoid Research Society, Abstr, 2005: 106.
10. Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem 2009; 145: 13-20.
11. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol - recent advances. Chem Biodivers 2007; 4: 1678-92.
12. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215.
13. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30: 515-27.
14. Ryberg E, Larsson N, Sjögren S et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-101.
15. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007; 150: 613-23.
16. Baker D, Pryce G, Davies WL, Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006; 27: 1-4.
17. Járai Z, Wagner JA, Varga K et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999; 96: 14136-41.
18. Johns DG, Behm DJ, Walker DJ et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 2007; 152: 825-31.
19. Whyte LS, Ryberg E, Sims NA et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA 2009; 106: 16511-6.
20. Schicho R, Bashashati M, Bawa M et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis 2010. DOI [Epub ahead of print].
21. Li YY, Sibaev A, Zhou MZ, Zhu GY, Yüce B, Storr M. The Chinese herbal preparation Qing Yi Tang (QYT) improves intestinal myoelectrical activity and increases intestinal transit during acute pancreatitis in rodents. Phytother Res 2007; 21: 324-31.
22. Li YY, Li YN, Ni JB et al. Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus. Neurogastroenterol Motil 2010; 22: 350-e88.
23. Li YY, Li XJ, Lv S et al. Ascitic fluid and serum from rats with acute pancreatitis injure rat pancreatic tissues and alter the expression of heat shock protein 60. Cell Stress Chaperones 2010; 15: 583-91.
24. De Filippis D, Iuvone T, d'amico A et al. Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase. Neurogastroenterol Motil 2008; 20: 919-27.
25. Feng M, Qin J, Wang C et al. Estradiol upregulates the expression of oxytocin receptor in colon in rats. Am J Physiol Endocrinol Metab 2009; 296: E1059-66.
26. 2+ current identified in freshly isolated interstitial cells of cajal (ICC) of guinea-pig stomach. Korean J Physiol Pharmacol 2008; 12: 323-30.
27. Ohama T, Hori M, Ozaki H. Mechanism of abnormal intestinal motility in inflammatory bowel disease: how smooth muscle contraction is reduced? J Smooth Muscle Res 2007; 43: 43-54.
28. Schwarz NT, Engel B, Eskandari MK, Kalff JC, Grandis JR, Bauer AJ. Lipopolysaccharide preconditioning and cross-tolerance: the induction of protective mechanisms for rat intestinal ileus. Gastroenterology 2002; 123: 586-98.
29. Rebollar E, Arruebo MP, Plaza MA, Murillo MD. Effect of lipopolysaccharide on rabbit small intestine muscle contractility in vitro: role of prostaglandins. Neurogastroenterol Motil 2002; 14: 633-42.
30. Fagundes DS, Gonzalo S, Arruebo MP, Plaza MA, Murillo MD. Melatonin and Trolox ameliorate duodenal LPS-induced disturbances and oxidative stress. Dig Liver Dis 2010; 42: 40-4.
31. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010; 126: 21-38.
32. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008; 57: 1140-55.
33. Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 2007; 152: 984-6.
34. Staton PC, Hatcher JP, Walker DJ et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008; 139: 225-36.
35. Sanders KM, Koh SD, Ward SM. Interstitial cells of cajal as pacemakers in the gastrointestinal tract. Annu Rev Physiol 2006; 68: 307-43.
36. Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxideproduction in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 2006; 399: 91-5.
37. Layman JM, Milton AS. Some actions of delta-1 tetrahydrocannabinol and cannabidiol at cholinergic junctions. Br J Pharmacol 1971; 41: 379P-80P.
38. Capasso R, Borrelli F, Aviello G et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol 2008; 154: 1001-8.
39. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008; 30: 271-80.
40. Pisanti S, Malfitano AM, Grimaldi C et al. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract Res Clin Endocrinol Metab 2009; 23: 117-31.
41. Wright K, Rooney N, Feeney M et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005; 129: 437-53.
42. Borrelli F, Aviello G, Romano B et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med 2009; 87: 1111-21.